Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts Carter Gould - Barclays Carter Gould Great. All right. Good morning. And welcome to the Barclays Global Healthcare Conference. My name is Carter Gould covering large-cap biopharma here at Barclays. Welcome, everyone. I’m pleased to welcome Regeneron Pharmaceuticals to ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Barclays 26th Annual Global Healthcare Conference Transcript March 12, 2024 11:15 AM ET Executives Chris Fenimore - Chief Financial Officer Ryan Crowe - Vice President, Investor Relations Analysts Carter Gould - Barclays Carter Gould Great. All right. Good morning. And welcome to the Barclays Global Healthcare Conference. My name is Carter Gould covering large-cap biopharma here at Barclays. Welcome, everyone. I’m pleased to welcome Regeneron Pharmaceuticals to ...

TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent® (alirocumab) as an adjunct to diet and other low-density lipoprotein cholesterol (LDL-C) lowering therapies to include pediatric patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH). "Many children with heterozygous familial hypercholesterolemia (HeFH) are able to substantially improve their LD ...

Published results show EYLEA HD with extended 12- or 16-week dosing regimens demonstrated non-inferior vision gains to standard of care EYLEA® (aflibercept) Injection 2 mg with fixed 8-week dosing in patients with wAMD and DME in the first year EYLEA HD has shown impressive durable visual improvements and rapid and resilient fluid control with a safety profile comparable to EYLEA Extended dosing intervals with EYLEA HD have the potential to substantially reduce treatment burden for patients EYLEA HD has bee ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) TD Cowen 44th Annual Health Care Conference March 6, 2024 11:10 AM ET Company Participants Marion McCourt - EVP of Commercial Ryan Crowe - SVP and Head of IR Conference Call Participants Tyler Van Buren - TD Cowen Tyler Van Buren All right. Good morning, everyone. Thanks again for being here at the TD Cowen 44th Annual Healthcare Conference Day 3. My name is Tyler Van Buren, your senior biotech analyst at TD Cowen. For the next session, we have a fireside chat w ...

Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation Priority Review granted based on positive results from two Phase 3 trialsIf approved, Dupixent would be the only biologic therapy for COPD and the first new treatment approach for the disease in more than a decadeRegulatory submissions are also under review in China and Europe Paris and Tarrytown, N.Y. February 23, 2024. The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental ...

Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU) Approval based primarily on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placeboCSU is the fifth approved indication for Dupixent in Japan and the sixth indication for Dupixent globally Paris and Tarrytown, N.Y. February 16, 2024. The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent® (dupilumab) for the treatment ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Oppenheimer 34th Annual Healthcare Life Sciences Conference February 14, 2024 1:20 PM ET Company Participants Ryan Crowe - SVP, IR David Snow - SVP, Global Head of Dupixent franchise Conference Call Participants Hartaj Singh - Oppenheimer Hartaj Singh Great. Thank you, everybody, for joining us on the second day here of this track of the Oppenheimer Healthcare Conference of 2024. Got David Snow, the SVP and the Global Head of Dupixent franchise; and Ryan Crowe, ...

Nemes Laszlo/iStock via Getty Images Regeneron Pharmaceuticals (NASDAQ:REGN) has been one of my favorite growth stocks over the past several years. In fact, REGN is one of my "Top Ideas" in the Compounding Healthcare investing group on Seeking Alpha. Yet, I have never published a premium article covering Regeneron for Seeking Alpha despite all of their R&D and financial achievements. Now, years later, I am deciding to post on Regeneron not because I am overly bullish on the ticker, but because I have been d ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34446 ...